A twist in the IO tail

Going beyond the obvious conclusion with anti-LAG3 therapy

May 19, 2021

Potential of Immunometabolism to Enhance CAR T cell therapy

How can we use metabolic reprogramming to enhance CAR T cell therapy?

August 18, 2020

Highlighting an under-rated clinical development at ASCO20

Another fine example of how our understanding of the biology underpinning a certain type of cancer can lead to drugging the undruggable (no, it's not KRAS!)

May 14, 2020

The next wave of IO agents for combination therapies

Reprogramming the tumour microenvironment - can it be done and if so, how and what should be targeted?

March 12, 2020

The Future of Oncology R&D

Six key strategic factors to consider going forward in the quest for future oncology R&D pipelines

January 6, 2020

A novel approach to targeting BRAF and KRAS mutant cancers

How do we go about targeting KRAS mutations beyond G12C? Here's one elegant way that is promising yet very early in which it could be approached...

October 23, 2019

Eyes on CAR-T Cell Therapy in Europe – Future Directions

There are some potential unexpected new pretenders to the Novartis and Kite's CAR-T cell therapies in Europe. We discuss what they are and why they should be taken seriously.

October 17, 2019

Insights from KEYNOTE-522 in early stage TNBC

As checkpoint therapies start moving into early stage disease, how do we go about deciding which people to treat? An example using TNBC.

October 15, 2019

New directions in HR-positive breast cancer

Where are CDK4/6 inhibitors going and are there new opportunities for this class of agents outside of HR+/HER2- breast cancer?

October 14, 2019

PARP inhibition in metastatic prostate cancer

What can we learn from the phase 2 trials with PARP inhibitors in mCRPC? Quite a lot, it would seem...

October 9, 2019

ESMO19 Day 4 Highlights including the PROfound trial in advanced prostate cancer

Highlights from the PROfound trial in advanced prostate cancer and other stories of interest

September 30, 2019

ESMO19 Day 3 Highlights and Commentary

Key findings and commentary on the third day of ESMO

September 29, 2019

Insights on osimertinib in 1L NSCLC from the lens of the FLAURA trial

A look at the FLAURA overall survival results and what we can learn from the phase 3 trial

September 28, 2019

Update on Amgen’s KRAS inhibitor in solid tumours

We saw signs of activity from Amgen's KRAS G12C inhibitor in lung cancer at WCLC so it's time to look at what happens in colorectal cancer.

September 28, 2019

ESMO19 Highlights from Day 2

Review and analysis of key trials presented on the second day at ESMO 2019

September 28, 2019

ESMO19 Highlights from Day 1

Commentary and Insights from Day 1 of ESMO19

September 27, 2019

ESMO19 Preview 3 – Tackling immune suppression

Some early stage oncology agents in development that seek to target and tackle inhibitory and immunosuppressive factors

September 23, 2019

ESMO19 Preview 2 – Targeting Synthetic Lethality and Immune Response in GU malignancies

Preview of ESMO19 around targeting DNA damage repair (DDR) for GU cancers.

September 18, 2019

Controversies in triple negative breast cancer at ESMO19

What should we be watching out for in terms of red and green flags at ESMO on the breast cancer IO front?

September 16, 2019

Novel DDR combinations and regimens that could make a difference

Latest preclinical and clinical news and readouts as well as forthcoming trial presentations to look forward to in the DDR space

August 16, 2019